New pill takes on Hard-to-Treat lymphoma in early trial
NCT ID NCT07283796
First seen Jan 07, 2026 · Last updated May 14, 2026 · Updated 26 times
Summary
This early-phase study tests an experimental tablet (HSK47977) in 110 adults whose Non-Hodgkin's lymphoma has returned or stopped responding to treatment. The main goals are to find the safest dose and check for side effects, while also looking at how well the drug works. Participants must have measurable tumors and adequate organ function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NHL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chinese Academy of Medical Sciences Blood Diseases Hospital
RECRUITINGTianjin, China
Conditions
Explore the condition pages connected to this study.